Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After One Year

Clinical Pharmacology and Therapeutics - United States
doi 10.1002/cpt.1321
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Pregnancy Outcome After Exposure to Migalastat for Fabry Disease: A Clinical Report

Case Reports in Obstetrics and Gynecology
2019English

Strong Increase of Leukocyte Apha‐galactosidase a Activity in Two Male Patients With Fabry Disease Following Oral Chaperone Therapy

Molecular genetics & genomic medicine
GeneticsMolecular Biology
2019English

Safety of Switching to Migalastat From Enzyme Replacement Therapy in Fabry Disease: Experience From the Phase 3 ATTRACT Study

American Journal of Medical Genetics, Part A
Genetics
2019English

Quantitative Changes of Melanoma-Associated Antigens as a Biomarker for Targeted Therapy Response

Experimental Dermatology
BiochemistryDermatologyMolecular Biology
2016English

After One Year

International Journal of Plant Biology
Plant Science
2011English

After One Year ...

GDR Bulletin
1975English

Serum Osteoprotegerin as a Biomarker for Vascular Disease

American Journal of Cardiology
Cardiovascular MedicineCardiology
2007English

Changes in Deceased Donor Kidney Transplantation One Year After KAS Implementation

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2016English

Renal Aspects and Enzyme Replacement Therapy of Fabry Disease

2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy